No correlation between plasma NMDA-related glutamatergic amino acid levels and cognitive function in medicated patients with schizophrenia

International Journal of Psychiatry in Medicine

Volumn 44, Issue 1, 2012, Pages 17-27

  Ohnuma, Tohru ^a   Sakai, Yoshie ^a   Maeshima, Hitoshi ^a   Higa, Motoyuki ^a   Hanzawa, Ryo ^a   Kitazawa, Maiko ^a   Hotta, Yuri ^a   Katsuta, Narimasa ^a   Takebayashi, Yuto ^a   Shibata, Nobuto ^a   Arai, Heii ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

cognitive function; glutamate; plasma; schizophrenia; serine

Indexed keywords

ALANINE; BENZATROPINE; BLONANSERIN; CHLORPROMAZINE; GLUTAMIC ACID; GLYCINE; HALOPERIDOL; LEVOMEPROMAZINE; OLANZAPINE; PEROSPIRONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERINE; SULTOPRIDE;

ADULT; AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CATATONIC SCHIZOPHRENIA; CLINICAL ASSESSMENT; COGNITION; DSM-IV; FEMALE; HEBEPHRENIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERVIEW; JAPANESE; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PARANOID SCHIZOPHRENIA; PREFRONTAL CORTEX; PSYCHIATRIST; RESIDUAL SCHIZOPHRENIA; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ALANINE; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BIOLOGICAL MARKERS; BRIEF PSYCHIATRIC RATING SCALE; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; GLYCINE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; REFERENCE VALUES; SCHIZOPHRENIA; SERINE; YOUNG ADULT;

EID: 84868680041     PISSN: 00912174     EISSN: 15413527     Source Type: Journal    
DOI: 10.2190/PM.44.1.b     Document Type: Article

References (42)

1. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 1991;148:1301-1308.
2. Ohnuma T, Suzuki T, Arai H. Hypothesis: Minimal changes in neural transmission in schizophrenia: Decreased glutamatergic and GABAergic functions in the pre-frontal cortex. Progress in Neuropsychopharmacology and Biological Psychiatry 2005;29(6):889-894.
3. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry 1995;52(12):998-1007.
4. Andersen JD, Pouzet B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine. Neuropsychopharmacology 2004; 29(6):1080-1090. (Pubitemid 38670046)
5. Hashimoto K, Fujita Y, Ishima T, Chaki S, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine. The Journal of European College of Neuropsychopharmacology 2008;18(6):414-421. (Pubitemid 351608551)
6. Javitt DC. Treatment of negative and cognitive symptoms. Current Psychiatry Reports 1999;1(1):25-30.
7. Tamminga CA. The neurobiology of cognition in schizophrenia. The Journal of Clinical Psychiatry 2006;67(9):e11.
8. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, et al. Decreased serum levels of D-serine in patients with schizophrenia: Evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Archives of General Psychiatry 2003;60(6):572-576. (Pubitemid 36682314)
9. Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, et al. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. The American Journal of Psychiatry 2005;162(9):1738-1740. (Pubitemid 41318246)
10. Hatano T, Ohnuma T, Sakai Y, Shibata N, Maeshima H, Hanzawa R, et al. Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve\Results from the Juntendo University Schizophrenia Projects (JUSP). Psychiatry Research 2010;177(1-2):27-31.
11. Maeshima H, Ohnuma T, Sakai Y, Shibata N, Baba H, Ihara H, et al. Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia\Juntendo University Schizophrenia Projects (JUSP). Progress in Neuropsychopharmacology and Biological Psychiatry 2007;31(7): 1410-1418. (Pubitemid 47302552)
12. Ohnuma T, Sakai Y, Maeshima H, Hatano T, Hanzawa R, Abe S, et al. Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: Results from the Juntendo University Schizophrenia Projects (JUSP). Progress in Neuropsychopharmacology and Biological Psychiatry 2008;32(8):1905-1912.
13. Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC. High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophrenia Research 2007;91(1-3):14-21.
14. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to anti-psychotics for the treatment of schizophrenia. Biological Psychiatry 1998;44(11): 1081-1089. (Pubitemid 28547143)
15. Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 2006;59(3):230-234. (Pubitemid 43208969)
16. Bauer D, Hamacher K, Broer S, Pauleit D, Palm C, Zilles K, et al. Preferred stereo-selective brain uptake of D-serine\A modulator of glutamatergic neurotransmission. Nuclear Medicine and Biology 2005;32(8):793-797. (Pubitemid 41505312)
17. Nishikawa T. Metabolism and functional roles of endogenous D-serine in mammalian brains. Biological and Pharmaceutical Bulletin 2005;28(9):1561-1565. (Pubitemid 41324109)
18. Hashimoto K, Shimizu E, Iyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Current Psychiatry Review 2005;1:151-163.
19. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. Biometrics Research Department, New York State Psychiatric Institute, New York, 1995.
20. Overall JE GO. The Brief Psychiatry Rating Scale. Psychological Report 1962; 10:99-812.
21. Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatrica Scandinavica 1986;326:1-37.
22. Davis JM. Comparative doses and costs of antipsychotic medication. Archives of General Psychiatry 1976;33(7):858-861.
23. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Jr., et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 1997; 17(5):407-418. (Pubitemid 27414397)
24. Higa M, Ohnuma T, Maeshima H, Hatano T, Hanzawa R, Shibata N, et al. Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: Results from the Juntendo University Schizophrenia Projects (JUSP). Neuroscience Letters 2010;469(1):55-59.
25. Fletcher PC, Frith CD, Grasby PM, Friston KJ, Dolan RJ. Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia. The Journal of Neuroscience 1996;16(21):7055-7062. (Pubitemid 26359384)
26. Gaillard WD, Hertz-Pannier L, Mott SH, Barnett AS, LeBihan D, Theodore WH. Functional anatomy of cognitive development: fMRI of verbal fluency in children and adults. Neurology 2000;54(1):180-185. (Pubitemid 30038757)
27. Cohen JD, Servan-Schreiber D. Context, cortex, and dopamine: A connectionist approach to behavior and biology in schizophrenia. Psychological Review 1992; 99(1):45-77.
28. Goethals I, Audenaert K, Jacobs F, Lannoo E, Van de Wiele C, Ham H, Otte A, et al. Cognitive neuroactivation using SPECT and the Stroop Colored Word Test in patients with diffuse brain injury. Journal of Neurotrauma 2004;21(8): 1059-1069.
29. Minatogawa-Chang TM, Schaufelberger MS, Ayres AM, Duran FL, Gutt EK, Murray RM, et al. Cognitive performance is related to cortical grey matter volumes in early stages of schizophrenia: A population-based study of first-episode psychosis. Schizophrenia Research 2009;113(2-3):200-209.
30. Stone M, Gabrieli JD, Stebbins GT, Sullivan EV. Working and strategic memory deficits in schizophrenia. Neuropsychology 1998;12(2):278-288. (Pubitemid 28188868)
31. Matsuoka K, Uno M, Kasai K, Koyama K, Kim Y. Estimation of premorbid IQ in individuals with Alzheimer's disease using Japanese ideographic script (Kanji) compound words: Japanese version of National Adult Reading Test. Psychiatry and Clinical Neuroscience 2006;60(3):332-339. (Pubitemid 43736398)
32. Carter CS, Mintun M, Cohen JD. Interference and facilitation effects during selective attention: An H215O PET study of Stroop task performance. Neuroimage 1995; 2(4):264-272.
33. Ohnuma T, Arai H. Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia. Progress in Neuro-psychopharmacology and Biological Psychiatry 2011;35(1):29-39.
34. Mahurin RK, Velligan DI, Miller AL. Executive-frontal lobe cognitive dysfunction in schizophrenia: A symptom subtype analysis. Psychiatry Research 1998;79(2): 139-149. (Pubitemid 28308487)
35. Savilla K, Kettler L, Galletly C. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. The Australian and New Zealand Journal of Psychiatry 2008;42(6):496-504. (Pubitemid 351891128)
36. Conklin HM, Curtis CE, Katsanis J, Iacono WG. Verbal working memory impairment in schizophrenia patients and their first-degree relatives: Evidence from the digit span task. American Journal of Psychiatry 2000;157(2):275-277. (Pubitemid 30080912)
37. Garlinghouse MA, Roth RM, Isquith PK, Flashman LA, Saykin AJ. Subjective rating of working memory is associated with frontal lobe volume in schizophrenia. Schizophrenia Research 2010;120(1-3):71-75.
38. Twamley EW, Palmer BW, Jeste DV, Taylor MJ, Heaton RK. Transient and executive function working memory in schizophrenia. Schizophrenia Research 2006;87(1-3): 185-190. (Pubitemid 44467853)
39. Nakano Y, Baba H, Maeshima H, Kitajima A, Sakai Y, Baba K, et al. Executive dysfunction in medicated, remitted state of major depression. Journal of Affective Disorders 2008;111(1):46-51.
40. Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, et al. High dose D-serine in the treatment of schizophrenia. Schizophrenia Research 2010; 121(1-3):125-130.
41. Shad MU, Tamminga CA, Cullum M, Haas GL, Keshavan MS. Insight and frontal cortical function in schizophrenia: A review. Schizophrenia Research 2006;86(1-3): 54-70.
42. Carter CS, Barch DM, Bullmore E, Breiling J, Buchanan RW, Butler P, et al. Cognitive neuroscience treatment research to improve cognition in schizophrenia II: Developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biological Psychiatry 2011;70(1):7-12.